SCHEMBL16123733

SCHEMBL16123733

CN(C)CCCNCc1cc(-c2ccccc2)nc2cc(Cl)ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MOK Q9UQ07 4/20 0.53
TACR3 P29371 1/20 0.48
SLC2A1 P11166 2/20 0.47
TERT O14746 2/20 0.46
FERMT2 Q96AC1 1/20 0.46
POLB P06746 3/20 0.45
ACP1 P24666 1/20 0.45
CHEK1 O14757 1/20 0.42
ITGB2 P05107 1/20 0.42
ICAM1 P05362 1/20 0.42
ITGAL P20701 1/20 0.42
ALDH1A1 P00352 2/20 0.41
RAD52 P43351 2/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
KDM4E B2RXH2 1/20 0.41
FLT3 P36888 1/20 0.41
NPC1 O15118 1/20 0.41
APOBEC3A P31941 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28246011 0.85 TACR3 (0.50) MOKTACR3SLC2A1FERMT2MAPK1
Hydrochloric Acid SCHEMBL28245269 0.84 TACR3 (0.49) MOKTACR3SLC2A1MAPK1
Hydrochloric Acid SCHEMBL28245254 0.84 TACR3 (0.49) MOKTACR3SLC2A1MAPK1
SCHEMBL16123693 0.80 MOK (0.47) MOKTACR3SLC2A1POLBACP1
SCHEMBL16096585 0.80 TACR3 (0.48) MOKTACR3KDM4EMAPK1
Hydrochloric Acid SCHEMBL16101609 0.79 TACR3 (0.47) MOKTACR3SLC2A1KDM4EMAPK1
Hydrochloric Acid SCHEMBL18093609 0.79 TACR3 (0.47) MOKTACR3SLC2A1KDM4EMAPK1
SCHEMBL16099320 0.79 HTT (0.61) MOKTACR3POLBKDM4EKMT2A
SCHEMBL20460644 0.79 SLC2A1 (0.44) SLC2A1FERMT2POLBACP1ALDH1A1
Hydrochloric Acid SCHEMBL16098467 0.78 HTT (0.60) MOKTACR3POLBKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10179770-B2 Quinolines derivatives as novel anticancer agents GENOSCIENCE PHARMA (FR) 2019-01-15 US disclosed
EP-2976333-B1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA SAS (FR) 2018-08-08 EP disclosed
US-20160280653-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA (FR) 2016-09-29 US disclosed
US-20160280653-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA (FR) 2016-09-29 US disclosed
WO-2014147611-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA (FR) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10179770-B2 Quinolines derivatives as novel anticancer agents NQO2, MKI67, NQO1 MOK 4634/4885TACR3 2340/4885SLC2A1 3982/4885
US-20160280653-A1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS NQO2, MKI67, NQO1 MOK 4634/4885TACR3 2340/4885SLC2A1 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.